logo

  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Lidocaine Market, By Indication (Ointments, Injections, Creams, Gels, Aerosol Liquids), By Application (Cardiac Arrhythmia, Dentistry, Cosmetic, Epilepsy, and Others) opportunities and forecast 2020-2027

  • DLR2171
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Lidocaine is medication generally used to numb tissues in specific area. The medication helps to decrease sharp burning pains and discomfort caused by the skin areas that are subtle to touch. It is utmost used as local anaesthetic. It is also used to lessen pain caused bythe skin irritations such as insect bites, sunburn, and minor cuts.

Major drivers for growth of lidocaine market around the globe are growing aging patient population, the rising incidences of dental caries, rising application for lidocaine in dental procedures, and other periodontal diseases. Severe regulatory policies limit the growth of the market over the forecast period.

Segment Overview

The promptly increasing aging population over the world is leading to the growth of lidocaine market. With growing age of humans, teeth become incapable of the normal chewing, and aged population suffers from various other serious health issues. The medication is one of the most widely chosen to offer pain-free treatments to the geriatric patients at the time of surgeries and for the other dental treatments.

The older population face some problems after certain age, which includes dental caries, oral cancer, tooth loss, periodontics, arrhythmia, cardiac disorders, and many others. Therefore, the rise in the use of lidocaine to treat the issues is apparent, which would lead to growth of the lidocaine market.

Regional Overview

The market, based on region, is been divided into the North America, Europe, the Middle East & Africa and the Asia-Pacific. In the North America, lidocaine market is undergoing tremendous development due to growing R&D activities, increasing number of surgeries, and growing demand for the lidocaine formulations. As per theCenter for Disease Control and Prevention (CDC), total of 14.2 million operational procedures were accomplished in inpatient setting in the U.S. hospitals in the 2014. Furthermore, rising number of cosmetic and plastic surgeries, growing healthcare spending, and the medical tourism in the U.S. is anticipated to boost the market growth in region. According to American Society of Plastic Surgeons, almost 17.5 million cosmetic processes were performed in U.S. in 2017. Thus, the market in region is expected to be largest during the valuation period.

The European market for the lidocaine is anticipated to be second-largest during forecast period. In Europe is anticipated to be driven by growing number of surgical processes in region, high adoption of the lidocaine injections as the local anesthetics at the time of the surgeries, and considerable patient population. According to report published by German Society of Thoracic & Cardiovascular Surgery, total of 103,128 heart surgery processes were carried out in the Germany in 2016. All such factors are expected to boost the growth of market.

Competitor overview

In February 2017, the Septodont launched new facility near Paris, to manufacture the injectable dental aesthetic cartridges.
In September 2016, pharmaceutical company Glenmark got Abbreviated New Drug Application approval for the lidocaine ointment USP, 5 percent by U.S. FDA.
In June 2016, the AstraZeneca announced commercialization agreement with the Aspen Global Incorporated (AGI) with the aim to expand commercial reach for company’s anesthetic’s

In February 2016, the Septodont acquired DLA, injectable dental aesthetic producing plant in Brazil. Septodont strengthened its occurrence in Latin American region with the strategic action.

Key Players
  1. Boston Scientific Corporation
  2. Cogentix Medical
  3. Fujifilm Holdings Corporation
  4. Olympus Corporation
  5. PENTAX MEDICAL
  6. Endomed Systems
  7. KARL STORZ GmbH & Co. KG.
  8. SonoScape Medical Corp.
  9. SOFMEDICA,
  10. Perkin Elmer

Market Segmentation

By Formulation
  • Ointments
  • Injections
  • Creams
  • Gels
  • Aerosol Liquids
  • Others
By Application
  • Dentistry
  • Epilepsy
  • Cardiac Arrhythmia
  • Cosmetics
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 11

    2 Executive Summary 13

      3 Market Introduction 15

      • 3.1 Definition 16
      • 3.2 Scope of the Study 16
      • 3.3 Assumptions & Limitations 16
        • 3.3.1 Assumptions 16
        • 3.3.2 Limitations 16
      • 3.4 Market Structure 17

      4 Research Methodology 18

      • 4.1 Research Process 19
      • 4.2 Primary Research 20
      • 4.3 Secondary Research 21
      • 4.4 Market Size Estimation 21
      • 4.5 Forecast Model 22

      5 Market Dynamics 23

      • 5.1 Introduction 24
      • 5.2 Drivers 24
        • 5.2.1 Increasing aging patient population 24
        • 5.2.2 Increasing application of lidocaine in dental procedures 25
        • 5.2.3 Increasing incidences of dental caries and other periodontal diseases 25
      • 5.3 Restraints 26
        • 5.3.1 Stringent regulatory policies 26
      • 5.4 Opportunities 26
        • 5.4.1 Ongoing research and development activities 26

      6 Market Factor Analysis 27

      • 6.1.1 R&D and Designing 28
      • 6.1.2 Manufacturing 28
      • 6.1.3 Distribution & Sales 28
      • 6.1.4 Post-Sales Monitoring 28
    • 6.2 Porter’s Five Forces Model 29
      • 6.2.1 Bargaining Power of Suppliers 29
      • 6.2.2 Bargaining Power of Buyers 29
      • 6.2.3 Threat of New Entrants 30
      • 6.2.4 Threat of Substitutes 30
      • 6.2.5 Intense Rivalry 30

      • 7 Global Lidocaine Market, by Formulation 31

      • 7.1 Overview 32
      • 7.2 Injections 34
      • 7.4 Creams 35
      • 7.5 Ointments 35
      • 7.7 Gels 36
      • 7.8 Aerosol Liquids 36

      8 Global Lidocaine Market, by Application 37

      • 8.1 Overview 38
      • 8.2 Dentistry 40
      • 8.3 Cardiac Arrythmia 40
      • 8.4 Epilepsy 41
      • 8.5 Cosmetics 41

      9 Global Lidocaine Market, by Distribution Channel 43

      • 9.1 Overview 44
      • 9.2 Hospital Pharmacies 45
      • 9.3 Retail Pharmacies 46

      10 Global Lidocaine Market, by Region 47

      • 10.1 Overview 48
      • 10.2 Americas 50
        • 10.2.1 North America 52
          • 10.2.1.1 US 55
          • 10.2.1.2 Canada 56
        • 10.2.2 Latin America 58
      • 10.3 Europe 60
        • 10.3.1 Western Europe 62
          • 10.3.1.1 UK 65
          • 10.3.1.2 France 66
          • 10.3.1.3 Germany 68
          • 10.3.1.4 Italy 69
          • 10.3.1.5 Spain 71
          • 10.3.1.6 Rest of Western Europe 72
        • 10.3.2 Eastern Europe 74
      • 10.4 Asia-Pacific 76
        • 10.4.1 Japan 79
        • 10.4.2 China 80
        • 10.4.3 India 82
        • 10.4.4 Australia 83
        • 10.4.5 South Korea 85
        • 10.4.6 Rest of Asia-Pacific 86
      • 10.5 Middle East & Africa 88
        • 10.5.1 Middle East 90
        • 10.5.2 Africa 92

      11 Competitive Landscape 94

      • 11.1 Introduction 95

      12 Company Profile 96

      • 12.1 AstraZeneca 97
        • 12.1.1 Company Overview 97
        • 12.1.2 Financial Overview 97
        • 12.1.3 Products/Services Offered 97
        • 12.1.4 Key Developments 98
        • 12.1.5 SWOT Analysis 98
        • 12.1.6 Key Strategies 98
      • 12.2 Glenmark Pharmaceuticals Limited 99
        • 12.2.1 Financial Overview 99
        • 12.2.2 Products/Services Offered 99
        • 12.2.3 Key Developments 100
        • 12.2.4 SWOT Analysis 100
        • 12.2.5 Key Strategies 100
      • 12.3 Teligent 101
        • 12.3.1 Company Overview 101
        • 12.3.2 Financial Overview 101
        • 12.3.3 Products/Services Offered 102
        • 12.3.4 Key Developments 102
        • 12.3.5 SWOT Analysis 102
        • 12.3.6 Key Strategies 102
      • 12.4 Septodont Holding 103
        • 12.4.1 Company Overview 103
        • 12.4.2 Financial Overview 103
        • 12.4.3 Products/Services Offered 103
        • 12.4.4 Key Developments 103
        • 12.4.5 SWOT Analysis 104
        • 12.4.6 Key Strategies 104
      • 12.5 Amneal Pharmaceuticals LLC 105
        • 12.5.1 Company Overview 105
        • 12.5.2 Financial Overview 105
        • 12.5.3 Products/Services Offered 105
        • 12.5.4 Key Developments 105
        • 12.5.5 SWOT Analysis 106
        • 12.5.6 Key Strategies 106
      • 12.6 Taro Pharmaceutical Industries Ltd. 107
        • 12.6.1 Company Overview 107
        • 12.6.2 Financial Overview 107
        • 12.6.3 Products/Services Offered 108
        • 12.6.4 Key Developments 108
        • 12.6.5 SWOT Analysis 108
        • 12.6.6 Key Strategies 108
      • 12.7 Cambrex Corporation 109
        • 12.7.1 Company Overview 109
        • 12.7.2 Financial Overview 109
        • 12.7.3 Products/Services Offered 109
        • 12.7.4 Key Developments 110
        • 12.7.5 SWOT Analysis 110
        • 12.7.6 Key Strategies 110
      • 12.8 Centura Pharmaceuticals Store 111
        • 12.8.1 Company Overview 111
        • 12.8.2 Financial Overview 111
        • 12.8.3 Products/Services Offered 111
        • 12.8.4 Key Developments 111
        • 12.8.5 SWOT Analysis 111
        • 12.8.6 Key Strategies 111
      • 12.9 Proficient Rx LP 112
        • 12.9.1 Company Overview 112
        • 12.9.2 Financial Overview 112
        • 12.9.3 Products/Services Offered* 112
        • 12.9.4 Key Developments 112
        • 12.9.5 SWOT Analysis 112
        • 12.9.6 Key Strategies 112

      13 Appendix 113

      • 13.1 Discussion Blue Print 114

      Report You Might be Interested

      Keywords